Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

1. Manso, L.
2. Moreno Antón, F.
3. Izarzugaza Perón, Y.
4. Delgado Mingorance, J.I.
5. Borrega García, P.
6. Echarri González, M.J.
7. Martínez-Jañez, N.
8. López-González, A.
9. Olier Garate, C.
10. Ballesteros García, A.
11. Chacón López-Muñíz, I.
12. Ciruelos Gil, E.
13. García-Sáenz, J.A.
14. Paz-Ares, L.